查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1906301

全球 CD137 标靶治疗市场：市场机会、治疗方法、技术开发平台与临床试验展望（2026 年）

Global CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026
出版日期: | 出版商: KuicK Research | 英文 270 Pages | 商品交期: 最快1-2个工作天内

价格

全球 CD137 标靶治疗市场 - 市场机会、治疗方法、技术开发平台和临床试验展望（2026 年）要点：

  • 预计首支 CD137 标靶疗法将于 2030 年前上市。
  • CD137 标靶疗法临床试验概况：超过 90 种疗法
  • CD137 标靶疗法临床试验概况（按公司、国家/地区、适应症和阶段划分）
  • 大多数临床试验：III 期
  • 各公司 CD137 标靶疗法的专有技术平台
  • 全球和区域趋势（临床和商业）
  • CD137 标靶治疗方法

对 CD137 标靶疗法的需求CD137标靶疗法及其在本报告中的意义

CD137 (4-1BB) 是一种重要的共刺激受体，对 T 细胞的活化、存活和增殖至关重要。它也被认为在增强抗肿瘤免疫反应中发挥关键作用，使其成为癌症免疫疗法中最有价值的目标之一。儘管免疫肿瘤学近年来取得了进展，但目前的治疗方法，例如化疗和免疫检查点抑制剂，在疗效方面仍面临许多挑战，尤其是在实体瘤患者中。 CD137标靶疗法有望透过直接刺激肿瘤微环境中的免疫细胞并增强身体的抗癌能力来应对这些挑战。

本报告旨在探讨人们对CD137标靶疗法日益增长的兴趣，详细介绍正在进行的临床试验，介绍新兴技术，并介绍推动创新的公司。本报告从描述临床开发各个阶段的进展，到概述影响各种 CD137 标靶治疗策略未来发展的竞争格局和科学前景，重点阐述了 CD137 调控在肿瘤治疗中的潜力。

本报告涵盖的临床研究和试验概览

本报告全面深入地介绍了正在进行的 CD137 标靶治疗临床研究和试验，使利害关係人能够清晰了解该领域的治疗进展。报告分析了从早期试验到更高级研究的各个临床阶段。这些试验涉及多种适应症，尤其关注实体肿瘤和血液系统恶性肿瘤。报告还讨论了正在进行的联合治疗试验，重点阐述了 CD137 标靶药物如何与化疗和其他免疫疗法（包括 PD-1 抑制剂和 VEGF 抑制剂）联合使用，以提高整体疗效。本综述也总结了新兴的临床数据，并评估了标靶 CD137 疗法的安全性和有效性，为推进这些疗法的发展提供了重要见解。

本报告涵盖的技术平台

本报告进一步概述了推动标靶 CD137 疗法研发创新的技术平台。例如，AP Biosciences 的 T-cube 平台能够产生双特异性抗体，这些抗体仅在与肿瘤特异性抗原结合时才能透过 CD137 选择性地活化 T 细胞。这种特异性有望最大限度地减少脱靶毒性，例如其他免疫疗法中常见的细胞激素风暴。这些技术平台为更具标靶性、更安全、潜在更有效的治疗提供了环境，代表了癌症免疫疗法的突破。本报告概述了这些平台，并评估了它们对未来标靶 CD137 疗法的影响。

参与 CD137 标靶疗法研发的关键公司

老牌製药巨头和新兴生技公司都在 CD137 标靶疗法的研发中发挥主导作用。罗氏、Genmab 和四川百利药业等领先公司正积极推动 CD137 标靶疗法的临床试验。 ABL Bio 和 Pieris Pharmaceuticals 等中小型公司也透过探索新型双特异性抗体和递送系统，不断丰富研究领域。本报告深入分析了这些关键公司、其研发管线和策略，以及 CD137 标靶疗法的进展，清楚展现了这一快速发展领域的竞争格局。

报告：CD137 标靶疗法的未来发展方向

本报告对 CD137 标靶疗法的未来发展方向进行了全面且前瞻性的分析。该领域正不断发展，新的创新有望克服现有挑战，例如免疫抗药性和细胞激素释放症候群等副作用。此外，将CD137激动剂与其他免疫检查点抑制剂或标靶疗法合併应用的联合疗法，具有克服单药疗法限制的巨大潜力。鑑于正在进行的临床试验和不断涌现的数据，CD137标靶疗法有望在癌症治疗中发挥日益重要的作用。本报告深入分析了这些新兴趋势，使利害关係人能够预测这一前景广阔的领域未来的发展方向及其对肿瘤学领域的潜在影响。

目录

第一章：研究方法

第二章：CD137简介

  • 临床概述
  • CD137的生物学史
  • CD137拮抗剂时代
  • CD137的双向讯号传导

第三章：全球CD137标靶治疗市场展望

  • 当前研究和市场概况
  • 未来商用化机遇

第四章：CD137标靶治疗临床创新区域趋势

  • 中国
  • 韩国
  • 美国国家/地区
  • 欧洲
  • 澳大利亚

第五章 CD137 的角色及临床进展（依适应症划分）

  • 癌症
    • 白血病
    • 淋巴瘤
    • 肺癌
    • 黑色素瘤
    • 乳癌
    • 大肠直肠癌
  • 自体免疫疾病与发炎性疾病
  • 微生物感染
  • 神经系统疾病

第六章 CD137 标靶治疗临床试验的全球概览

  • 按公司
  • 依国家/地区
  • 按适应症
  • 依阶段

第七章 CD137 标靶治疗临床试验的见解（按公司、国家、适应症和阶段划分）

  • 研究
  • 临床前
  • I期
  • I/II期
  • II期
  • III期

第八章：各公司针对CD137标靶疗法的独特技术平台

第九章：CD137标靶疗法

  • 抗体
    • 单株抗体
    • 双特异性抗体策略
    • 三特异性抗体策略
    • 四特异性抗体策略
    • 单股可变片段
  • 胜肽
  • 基于蛋白质的疗法

第十章：联合疗法CD137标靶疗法

第十一章：竞争格局

  • ABL Bio
  • Adagene
  • Alligator Bioscience
  • BeOne Medicines
  • Bicycle Therapeutics
  • BioNTech
  • Crescendo Biologics
  • Compass Therapeutics
  • Eutilex
  • F-star Therapeutics
  • Genmab
  • NovaBridge Biosciences
  • Kyinno Biotechnology
  • Lyvgen Biopharma
  • Obsidian Therapeutics
  • OriCell Therapeutics
  • Palvella Therapeutics
  • 上海亨利生物科技
  • 四川百利药业
  • SystImmune

Global CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026 Report Highlights:

  • First CD137 Targeted Therapy Commercial Launch Expected By 2030
  • Insight On CD137 Targeted Therapies In Clinical Trials: > 90 Therapies
  • CD137 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
  • Highest Clinical Trials Phase: Phase III
  • CD137 Targeted Therapies Proprietary Technology Platforms By Companies
  • Global & Regional Trends (Clinical & Commercial)
  • Therapeutic Approaches For Targeting CD137

CD137 Targeted Therapies Need & Why This Report?

CD137 or 4-1BB, is a co-stimulatory receptor important for T-cell activation, survival, and expansion. It is also recognized for playing a critical role in augmenting anti-tumor immune responses, hence becoming one of the most valued targets in cancer immunotherapy. Notwithstanding recent progress made in immune oncology, current treatments such as chemotherapy and immune checkpoint inhibitors have some shortcomings regarding their efficacy among patients, especially those with solid tumors. CD137 targeting therapies can bridge these gaps through the direct stimulation of immune cells in the tumor microenvironment, leveraging the body to better combat cancer.

The report covers the increasing enthusiasm for CD137-targeted therapies, underlining the details of ongoing clinical trials, emerging technologies, and identifying companies that are driving the innovation process. It underlines the therapeutic potential of CD137 modulation in oncology: from describing progress made at different stages of clinical development to outlining the competitive and scientific landscape forming the future for various CD137-targeted treatment strategies.

Clinical Studies & Trials Insight Included In Report

The report provides comprehensive insights into the ongoing clinical studies and trials for CD137 targeted therapies, enabling stakeholders to take a clear view of the therapeutic progress of this field. An analysis is provided of various clinical stages that range from early-phase trials to more advanced studies. These trials involve research into a range of indications, with particular attention to solid tumors and hematological malignancies. Ongoing combination therapy trials are also discussed, concerned with the investigation into how agents targeting CD137 may act in concert with chemotherapies or other immunotherapies-including PD-1 or VEGF inhibitors-to improve overall efficacy. This review also identifies the emerging clinical data and assesses the safety and efficacy profiles of CD137-targeted therapies, providing critical insight into the way forward for these therapies.

Technology Platforms Included In Report

The report further profiles technology platforms driving innovations in CD137 targeted therapy development. Examples include AP Biosciences' T-cube, a platform enabling the creation of bispecific antibodies that selectively activate T-cells through CD137 only upon binding to tumor-specific antigens. This specificity offers the promise of minimal off-target toxicities, such as cytokine storms, common with other immune therapies. These technology platforms represent a quantum leap in cancer immunotherapy by providing an enabling environment for more targeted, safer, and probably more effective therapies. The report provides an overview of such platforms and assesses their implications for future CD137 targeted therapies.

Leading Companies Involved In R&D of CD137 Targeted Therapies

Established pharmaceutical giants and emerging biotech companies both lead in the development of CD137 targeted therapies. Major players such as Roche, Genmab, and Sichuan Baili Pharmaceutical are actively advancing their CD137-targeting therapies in clinical trials. Smaller firms like ABL Bio and Pieris Pharmaceuticals continue to bring in diversity into the research landscape by exploring novel bispecific antibodies and delivery systems. This report describes those key companies, insights into their pipelines and strategies, and the progress of their CD137 targeted therapies in order to give a clear picture of the competitive landscape in this rapidly evolving field.

Report Indicating Future Direction of CD137 Targeted Therapies

Looking ahead, the report comprehensively analyzes the future direction of CD137 targeted therapies. The landscape is continuously evolving, with new innovations likely to overcome some of the existing challenges related to immune resistance and side effects such as cytokine release syndrome. Furthermore, combination therapies that combine CD137 agonists with other immune checkpoint inhibitors or targeted treatments offer significant potential for overcoming limitations observed in monotherapies. In the context of ongoing clinical trials and the emergence of new data, the role of CD137 targeted therapies is likely to be increasingly important in cancer treatment. This report provides key insights into these emerging trends, enabling stakeholders to anticipate the future direction of this promising field and its likely impact on the oncology landscape.

Table of Contents

1. Research Methodology

2. Brief Introduction To CD137

  • 2.1 Clinical Overview
  • 2.2 Biological History Of CD137
  • 2.3 CD137 Hosting An Era Of Agonists Over Antagonists
  • 2.4 Bi-Directional Signaling In CD137

3. Global CD137 Targeted Therapy Market Outlook

  • 3.1 Current Research & Market Scenario
  • 3.2 Future Commercialization Opportunities

4. CD137 Targeted Therapy Clinical Innovation Trends By Region

  • 4.1 China
  • 4.2 South Korea
  • 4.3 US
  • 4.4 Europe
  • 4.5 Australia

5. CD137 Role & Clinical Progress By Indication

  • 5.1 Cancer
    • 5.1.1 Leukemia
    • 5.1.2 Lymphoma
    • 5.1.3 Lung Cancer
    • 5.1.4 Melanoma
    • 5.1.5 Breast Cancer
    • 5.1.6 Colorectal Cancer
  • 5.2 Autoimmune & Inflammatory Diseases
  • 5.3 Microbial Infections
  • 5.4 Neuronal Diseases

6. Global CD137 Targeted Therapies Clinical Trials Overview

  • 6.1 By Company
  • 6.2 By Country
  • 6.3 By Indication
  • 6.4 By Phase

7. CD137 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Phase I
  • 7.4 Phase I/II
  • 7.5 Phase II
  • 7.6 Phase III

8. CD137 Targeted Therapy Proprietary Technology Platforms By Companies

9. Therapeutic Approaches For Targeting CD137

  • 9.1 Antibodies
    • 9.1.1 Monoclonal antibodies
    • 9.1.2 Bispecific Antibody Centered Approaches
    • 9.1.3 Trispecific Antibody Established Strategies
    • 9.1.4 Tetraspecific Antibody Strategies
    • 9.1.5 Single-chain variable fragments
  • 9.2 Peptides
  • 9.3 Protein-Based Therapeutics

10. Combination Therapies With CD137 Targeted Therapy

11. Competitive Landscape

  • 11.1 ABL Bio
  • 11.2 Adagene
  • 11.3 Alligator Bioscience
  • 11.4 BeOne Medicines
  • 11.5 Bicycle Therapeutics
  • 11.6 BioNTech
  • 11.7 Crescendo Biologics
  • 11.8 Compass Therapeutics
  • 11.9 Eutilex
  • 11.10 F-star Therapeutics
  • 11.11 Genmab
  • 11.12 NovaBridge Biosciences
  • 11.13 Kyinno Biotechnology
  • 11.14 Lyvgen Biopharma
  • 11.15 Obsidian Therapeutics
  • 11.16 OriCell Therapeutics
  • 11.17 Palvella Therapeutics
  • 11.18 Shanghai Henlius Biotech
  • 11.19 Sichuan Baili Pharmaceutical
  • 11.20 SystImmune

List of Figures

  • Figure 2-1: Evolution Of Cancer Immunotherapy Approaches
  • Figure 2-2: Biological Effects Triggered By CD137 Stimulation
  • Figure 2-3: CD137 - Discovery & Early Biological Characterization
  • Figure 2-4: Mechanistic Pathways Triggered By CD137 Ligation
  • Figure 2-5: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms
  • Figure 2-6: Why CD137 Became An Important Target
  • Figure 2-7: Schematic Depiction Of Bidirectional Signaling By CD137-CD137L
  • Figure 2-8: CD137 - Forward Signaling Cascade in Immune Cells
  • Figure 2-9: CD137L - Reverse Signaling
  • Figure 2-10: Bidirectional Signaling Loop Between CD137 & CD137L
  • Figure 3-1: Global CD137 Targeting Therapy Market - Future Opportunities
  • Figure 5-1: Bidirectional CD137-CD137L Signaling in Leukemia Cell Survival
  • Figure 5-2: GNC-035-105 Phase Ib/II (NCT05944978) Study - Initiation & Completion Year
  • Figure 5-3: GNC-035-105 Phase I (NCT05944978) Study - Initiation & Completion Year
  • Figure 5-4: GNC-038-101 Phase I (NCT04606433) Study - Initiation & Completion Year
  • Figure 5-5: Lymphoma - CD137's Role In Countering Immune Evasion
  • Figure 5-6: BP41072 Phase I/II (NCT04077723) Study - Initiation & Completion Year
  • Figure 5-7: YH004003 Phase I (NCT05564806) Study - Initiation & Completion Year
  • Figure 5-8: IBD0333-101 Phase I/II (NCT06292208) Study - Initiation & Completion Year
  • Figure 5-9: Lung Cancer - Rationale For Targeting CD137
  • Figure 5-10: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
  • Figure 5-11: GCT1046-04 Phase 2 (NCT05117242) Study - Initiation & Completion Year
  • Figure 5-12: HLX35-FIH101 Phase I (NCT05360381) Study - Initiation & Completion Year
  • Figure 5-13: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
  • Figure 5-14: Melanoma - CD137 As A Costimulatory Driver Of Disease Immunity 71
  • Figure 5-15: FS222-19101 Phase I (NCT04740424) Study - Initiation & Completion Year
  • Figure 5-16: LBL-024-CN007 Phase I/II (NCT07099430) Study - Initiation & Completion Year
  • Figure 5-17: ABBIL1TY MELANOMA-07 Phase II (NCT06984328) Study - Initiation & Completion Year
  • Figure 5-18: Breast Cancer - Dual Role Of CD137 In Disease Biology
  • Figure 5-19: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
  • Figure 5-20: AP402-101 Phase I/II (NCT06669975) Study - Initiation & Completion Year
  • Figure 5-21: AVIATOR Phase 2 (NCT03414658) Study - Initiation & Completion Year
  • Figure 5-22: ADG106-T6002 Phase 1/2 (NCT05275777) Study - Initiation & Completion Year
  • Figure 5-23: YH32367-101 Phase I/II (NCT05523947) Study - Initiation & Completion Year
  • Figure 5-24: GNC-035-103 Phase I (NCT05160545) Study - Initiation & Completion Year
  • Figure 5-25: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
  • Figure 5-26: NCI-2018-01036 Phase 1 (NCT03290937) Study - Initiation & Completion Year
  • Figure 5-27: 1002-CL-0101 Phase I (NCT05719558) Study - Initiation & Completion Year
  • Figure 5-28: BNT314-02 Phase I/II (NCT07079631) Study - Initiation & Completion Year
  • Figure 5-29: CD137 - Dual Role In Immune Regulation
  • Figure 5-30: Microbial Infections - CD137 Expression & Immune Roles
  • Figure 5-31: CD137 In Neuroinflammation
  • Figure 6-1: Global – CD137 Targeted Therapies Clinical Pipeline by Company (Numbers), 2026
  • Figure 6-2: Global – CD137 Targeted Therapies Clinical Pipeline by Country (Numbers), 2026
  • Figure 6-3: Global – CD137 Targeted Therapies Clinical Pipeline by Indication (Numbers), 2026
  • Figure 6-4: Global – CD137 Targeted Therapies Clinical Pipeline by Phase (Numbers), 2026
  • Figure 8-1: Adagene – Anti CD137 NEObody ACG106
  • Figure 8-2: Adagene – Anti CD137 POWERbody ADG206
  • Figure 8-3: Genmab - DUObody Production Process
  • Figure 8-4: Genmab - DUObody Platform Detail
  • Figure 8-5: Crescendo Biologics - Humabody Structure
  • Figure 8-6: CB307 Humabody – Structure
  • Figure 8-7: Numab Therapeutics - MATCH Format
  • Figure 8-8: NM21-1480 - Structure
  • Figure 8-9: Systimmune – GNC-039 Structure
  • Figure 8-10: Systimmune – GNC-035 Structure
  • Figure 8-11: Systimmune – GNC-038 Structure
  • Figure 8-12: Merus – Multiclonics Structure
  • Figure 8-13: Chugai Pharmabody Research - Dual-Ig® Technology
  • Figure 8-14: Eutilex - Costim Platform Technology
  • Figure 8-15: AND-Body - Ampersand Biomedicines
  • Figure 8-16: X-body Platform - Leads Biolabs
  • Figure 8-17: T-cube Bispecific Antibody Platform - AP Biosciences
  • Figure 8-18: Grabody-T - ABL Bio
  • Figure 8-19: LEAD-452 Trimerbody – Structure
  • Figure 9-1: ATOR-1017 – Mechanism Of Action
  • Figure 9-2: EU101 – Mode Of Action
  • Figure 9-3: LVGN6051 – Mechanism Of Action
  • Figure 9-4: Ragistomig – Structure & Mechanism Of Action
  • Figure 9-5: FS120 – Improving PD-1 & Chemotherapy Responses
  • Figure 9-6: FS222 – Structure
  • Figure 9-7: FS222 – Mechanism Of Action
  • Figure 9-8: MP0310 – Mechanism Of Action
  • Figure 9-9: CD137 Targeting GNC Tetraspecific Antibodies
  • Figure 9-10: CD137 Targeting Peptide - Mechanism
  • Figure 9-11: CD137 Targeting Fusion Protein - Conditional Activation Design

List of Tables

  • Table 2-1: CD137 Expression Across Cell Types
  • Table 2-2: Comparison Of Antagonistic vs Agonistic Immunotherapies
  • Table 5-1: Lymphoma - Clinical Trials Underway for GNC-038 & GNC-035
  • Table 9-1: Some Bispecific Antibodies Targeting CD137 In Development
  • Table 9-2: Some Trispecific Antibodies Targeting CD137 In Development
  • Table 9-3: Some Tetraspecific Antibodies Targeting CD137 In Development
  • Table 10-1: Ongoing Clinical Trials Evaluating CD137 Antibody Combinations